Applying artificial intelligence techniques to cardiac ultrasound data may make it easier to identify patients with advanced ...

NEW ORLEANS , LA, UNITED STATES, March 19, 2026 /EINPresswire.com/ -- HeartLung.AI today announced that it will ...

The CHARM program consisted of 3 component trials, each comparing candesartan with placebo in a distinct population of patients with symptomatic heart failure [9]: CHARM-Alternative: patients with ...

Please provide your email address to receive an email when new articles are posted on . CAD was significantly prognostic of all-cause mortality in patients with heart failure. Mortality risk was ...

A substudy of the CHARM trial (see Trial Glossary below for expansion of all trial names mentioned in this article) has shown that the angiotensin receptor blocker (ARB) candesartan reduces the risk ...

Oral semaglutide reduces risk for heart failure events among patients with T2D and preexisting heart failure, according to the SOUL trial.

Late-stage failure of the left side of the heart is an often-fatal condition affecting hundreds of thousands of people in the U.S. alone. A mechanical heart pump can be a lifesaving intervention for ...

UVA Health researchers have developed a powerful new risk assessment tool for predicting outcomes in heart failure patients. The researchers have made the tool publicly available for free to ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing significant correlations. Higher scores correlate with increased heart failure ...

Doctors may soon be able to tell just how sick a heart failure patient really is by using a routine MRI scan, thanks to new research from the University of East Anglia. People with heart failure often ...

An innovative stem cell therapy approved for severe heart failure has been cleared for use in Japan. Here is why it matters ...